Shanghai, China - Frost & Sullivan, an international authoritative consulting agency, announced the results of the 2021 Best Practices Awards. As a comprehensive one-stop drug R&D and production service platform, Viva Biotech won the "2021 Greater China CRO Entrepreneurial Company of the Year".

The Frost & Sullivan "Best Practice Award" aims to commend outstanding companies around the world that continue to transform and break through, and pursue excellence in various fields such as leadership, technological innovation, and business development, etc. “Viva Biotech has distinguished itself through its innovative twin business model approach.

The combination of traditional CFS and unique EFS models allows Viva to enjoy a steady cash flow from clients looking for drug discovery services and high yield returns from investments. Through SBDD technology Viva Biotech has rapidly shortened the average six-year time-consuming for new drug development to three years.” Rathanesh Ramasundram, Associate Director of Frost & Sullivan said, “Through M&A and partnerships and by adopting a follow-the-molecule strategy for its two-wheel-driven model, Viva Biotech aims to become a comprehensive one-stop drug service platform provider. During the past two years, Viva Biotech has grown from a being a company with small market capitalization into a mid-sized, client-centric, and technology-driven CRO company.

Dr. Cheney Mao, Chairman and CEO of Viva Biotech, said, "Thanks to Frost & Sullivan for recognizing Viva Biotech's breakthrough business model and integrated platform. In the future, Viva will continue to build and continuously strengthen the support of outstanding start-up companies and talents, improve platform incubation and empowerment capabilities, expand and enhance the new drug research and development ecosystem, to become the cradle of biotech start-up companies from all over the world.”